We analysed the chemosensitivity of melanoma cells with acquired resistance to BRAF inhibitor (vemurafenib) (R) or combined BRAF and MEK inhibitor (vemurafenib and trametinib) (DR) treatment and of their sensitive (S) counterparts. This evidence concerns the gene BRAF and melanoma.